Study wrapper · #983
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.
Stefaniak E, Cui B, Yan X, et al. Chemical biology & drug design. 2026.
DOI: 10.1111/cbdd.70332PubMed: 42219795
Editor's note
A laboratory study using cell cultures and biochemical assays, not human data. SS-31 has been studied for its effects on mitochondrial function and protein aggregation relevant to Parkinson's-type pathology. Findings are early-stage and warrant further preclinical work.
Plain-language abstract
In cell and biochemical experiments, SS-31 reduced how alpha-synuclein bound to and clumped on membranes and helped restore mitochondrial function in nerve-like cells.
Related coverage
Supported
Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration.
Journal of gastroenterology and hepatologyn=——2026
Mixed
Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target.
Experimental neurologyn=——2026
Supported
Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.
Brain, behavior, and immunityn=——2026